A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer Andreas Granetzny, MD,

Slides:

Advertisements

Similar presentations

Ricardo L. Oliveira, MD, Moishe Liberman, MD, PhD

Advertisements

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Volume 131, Issue 4, Pages (April 2007)

Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor Marc Riquet, MD, PhD, Antoine Legras, MD,

Elizabeth A. David, MD, David T

Gender differences in non–small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002 Antonio L Visbal, MD, Brent.

Primary non-Hodgkin’s lymphoma of the lung

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Joshua E. Rosen, BASc, Hari B

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Lung cancer staging and treatment in multidisciplinary trials: cancer and leukemia group B cooperative group approach1 Mark J Krasna, MD, Carolyn E Reed,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor Marc Riquet, MD, PhD, Antoine Legras, MD,

Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience Tsuguo Naruke,

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Trimodal Therapy for Histologically Proven N2/3 Non–Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival Volker Steger, MD, Thorsten.

Surgical Treatment of Metachronous Second Primary Lung Cancer

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Superior sulcus (Pancoast) tumor: experience with 105 patients

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Dylan R. Nieman, MD, PhD, Christian G. Peyre, MD, Thomas J

Ricardo L. Oliveira, MD, Moishe Liberman, MD, PhD

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Prognostic factors in clinical stage I non–small cell lung cancer

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Prognostic Significance of Surgical-Pathologic N1 Lymph Node Involvement in Non- Small Cell Lung Cancer Adalet Demir, MD, Akif Turna, MD, PhD, FETCS,

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Selective Mediastinal Lymphadenectomy for Clinico-Surgical Stage I Non–Small Cell Lung Cancer Morihito Okada, MD, PhD, Toshihiko Sakamoto, MD, PhD, Tsuyoshi.

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations Jun Peng, MD, Wen-Ping Wang, MD, Ting Dong, MD, Jie Cai,

Value of systematic mediastinal lymph node dissection during pulmonary metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A Hatz, MD, Thomas.

Lewis Y antigen expression and postoperative survival in non–small cell lung cancer Fumihiro Tanaka, MD, Ryo Miyahara, MD, Yohsuke Ohtake, MD, Kazuhiro.

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Carcinoma of the esophagus: Prognostic significance of histologic type

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Problems related to TNM staging: Patients with stage III non–small cell lung cancer Kotaro Kameyama, MD, Cheng-long Huang, MD, Dage Liu, MD, Taku Okamoto,

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Edwin van Velzen, MD, Aart Brutel de la Rivière, MD, PhD, Hans J

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Immediate and Long-Term Survival After Surgery for Lung Cancer in Heart Transplant Recipients Patrick Bagan, MD, Jalal Assouad, MD, Pascal Berna, MD,

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Nonanatomic prognostic factors in resected nonsmall cell lung carcinoma: the importance of perineural invasion as a new prognostic marker Adnan Sayar,

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Lung Cancer Invading the Pericardium: Quantum of Lymph Nodes

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Survival and Prognosis After Pneumonectomy for Lung Cancer in the Elderly Yutaka Mizushima, Hirofumi Noto, Shigeki Sugiyama, Yoshinori Kusajima, Ryouhei.

Presentation transcript:

A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer Andreas Granetzny, MD, Eberhard Striehn, MD, Ulrich Bosse, MD, Wolfgang Wagner, MD, Olaf Koch, MD, Ulf Vogt, PhD, Peter Froeschle, MD, Folker Klinke, MD The Annals of Thoracic Surgery Volume 75, Issue 4, Pages 1107-1112 (April 2003) DOI: 10.1016/S0003-4975(02)04719-7

Fig 1 Postoperative tumor stage (n = 26). The Annals of Thoracic Surgery 2003 75, 1107-1112DOI: (10.1016/S0003-4975(02)04719-7)

Fig 2 Cumulative survival in clinical stage IIIA (solid line) and stage IIIB (dotted line). The difference between the two curves is not significant. The Annals of Thoracic Surgery 2003 75, 1107-1112DOI: (10.1016/S0003-4975(02)04719-7)

Fig 3 Long-term survival and remission rates in mediastinal lymph nodes. The difference between the groups with and without malignant cells in the mediastinal lymph nodes was significant (log rank p < 0.0117). Solid line = no malignant cells in mediastinal lymph node (n = 10); evenly dotted line = malignant cells in mediastinal lymph node (n = 16); and unevenly dotted line = no operation (n = 7). The Annals of Thoracic Surgery 2003 75, 1107-1112DOI: (10.1016/S0003-4975(02)04719-7)